Prevalence and factors contributing to first-line drug Resistance among patients attending the ART clinic at Mbarara Regional Referral Hospital. A cross-sectional study.
DOI:
https://doi.org/10.71020/ev0q3v63Keywords:
HIV drug resistance, First-line antiretroviral therapy, Adherence, Mbarara Regional Referral HospitalAbstract
Background:
The study aims to assess the prevalence and factors contributing to first-line drug Resistance among patients attending the ART clinic at Mbarara Regional Referral Hospital.
Methodology:
The study employed a descriptive cross-sectional design to assess the prevalence and contributing factors of HIV drug resistance among patients attending the ART clinic of Mbarara Regional Referral Hospital (MRRH). The target population consisted of adult patients (aged 18 years and above) living with HIV who are attending the ART clinic at MRRH and are on first-line ART regimens. systematic random sampling technique was used to ensure Representativeness and minimize selection bias.
Results:
Of the 87 participants whose records were reviewed, 11(12.6%) individuals were found to be resistant to first-line antiretroviral therapy, while the vast majority of the sample, 76(87.4%), were identified as non-resistant, indicating that their current first-line regimens remained effective at the time of the study. In terms of gender, 51(58.6%) were females while 36(41.4%) males. 44(50.6%) were married, 25(28.7%) divorced and 18(20.7%) single. 58(66.7%) resided in rural areas while 29(33.3%) in Urban or peri urban settings. Regarding ART adherence, 62(71.3%) of participants maintained good adherence (≥95%), but 9(10.3%) were classified as having poor adherence (<85%), while 16(18.4%) had a fair adherence status. 78(89.7%) of participants reported that they had received formal HIV education at the clinic, while 9(10.3%) did not. 24(27.6%) of the participants reported experiencing side effects from their medication, which is a factor that often leads to treatment interruptions
Conclusion:
The study concludes that HIV first-line drug resistance is a significant clinical challenge at Mbarara Regional Referral Hospital.
Recommendations:
MRRH should strengthen Community Drug Distribution Points (CDDPs) to reduce the transport burden for rural patients.
References
1. AkulliSan, A., Morrison, M., Garnett, G. P., Mnisi, Z., Lukhele, N., Bridenbecker, D., ... & Bershteyn, A. (2020). The effect of 90-90-90 on HIV-1 incidence and mortality in eSwatini: A mathematical modelling study. The Lancet HIV, 7(5), e348-e358. https://pmc.ncbi.nlm.nih.gov/articles/PMC7062634
2. Heestermans, T., Browne, J. L., Aitken, S. C., Vervoort, S. C., & Klipstein-Grobusch, K. (2016). Determinants of adherence to antiretroviral therapy among HIV-positive adults in sub- Saharan Africa: A systematic review. BMJ Global Health, 1(4), e000125. https://gh.bmj.com/content/1/4/e000125
3. Kiros, M., Mirin, T., Biset, S., Getu, B. D., Getachew, M., & Alemu, A. (2025). Prevalence and factors associated with HIV drug resistance among adult persons living with HIV/AIDS in nine countries of Sub-Saharan Africa using population-based HIV impact assessments. BMC Public Health, 25(1), 1-12. https://link.springer.com/article/10.1186/s12889-025- 24633-9
4. Kyaw, N. T., Harries, A. D., Kumar, A. M., O, M. M., Kyaw, K. W., Win, T., ... & Oo, H. N. (2016). High rate of virological failure and low rate of switching to second-line treatment among adolescents and adults living with HIV on first-line ART in Myanmar, 2005-2015. PLoS One, 11(2), e0151789. https://pmc.ncbi.nlm.nih.gov/articles/PMC4879357
5. Lee, G. Q., Bangsberg, D. R., Muzoora, C., Boum, Y., Oyugi, J. H., Emenyonu, N., ... & Hunt, P. W. (2014). Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda. AIDS Research and Human Retroviruses, 30(9), 896-906. https://www.liebertpub.com/doi/10.1089/aid.2014.0034
6. Machava, M. A., Sacoor, C., Fernandes, Q., Macuamule, C., de Schacht, C., Nhangave, A., ... & Chongo, P. (2024). Sociodemographic factors associated with non-disclosure of HIV serostatus to sexual partners in Maputo, Mozambique. Scientific Reports, 14(1), 72430. https://www.nature.com/articles/s41598-024-72430-y
7. Mbarara Regional Referral Hospital. (2024). Annual HIV clinic report. Mbarara, Uganda: MRRH.
8. Miruka, F. O., Nyanga, N., Otieno, G., Onyango, R., Ngugi, C., & Masaba, R. (2024). Factors associated with drug resistance mutations among antiretroviral therapy-experienced adolescents living with HIV in South Rift Valley, Kenya. Journal of Public Health in Africa, 15(1), 1488. https://publichealthinafrica.org/index.php/jphia/article/view/1488/2542
9. Ssentongo, P., Ba, D. M., Fronterre, C., Xing, J., Chinchilli, V., & Ssentongo, A. E. (2025).
Global, regional, and national prevalence of HIV-1 drug resistance in treatment-naive and treatment-experienced children and adolescents: a systematic review and meta-analysis.
eClinicalMedicine, 68, 102438. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00438-3/fulltext
10. Uganda Ministry of Health. (2022). National HIV/AIDS strategic plan 2020/21-2024/25.
Kampala: MOH.
11. Uganda Virus Research Institute. (2018). National HIV drug resistance prevention, monitoring and surveillance activities: National status report. https://www.uvri.go.ug/sites/default/files/files/HIVDR%20REPORT%20%20_Draft%20 9.pdf
12. Watera, C., Mukiza, N., Isabwe, M., Owora, J., Nangendo, F., Kiwanuka, G., ... & Kaleebu, P. (2021). HIV drug resistance among adults initiating antiretroviral therapy in Uganda.
Journal of Antimicrobial Chemotherapy, 76(9),2407-2414. https://academic.oup.com/jac/article/76/9/2407/6276545
13. World Health Organization. (2024). HIV drug resistance – brief report 2024. https://www.who.int/publications/i/item/9789240086319
14. World Health Organization. (2025). Fact sheet: HIV drug resistance. https://www.who.int/news- room/fact-sheets/detail/hiv-drug-resistance
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Ignatious Naijuka, Hasifa Nansereko, Ronald Mbidde, Dr. Jane Frank Nalubega, Francisco Ssemuwemba
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in any of our journals retain the copyright to their work but agree to grant Burundi Publishing the right of first publication. All articles are published under a Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This promotes transparency and fosters wide dissemination of the research.
